Telix Pharmaceuticals Limited reported financial results for the first half of 2025, with revenue reaching $390.4 million, up 63% from the previous year. The company’s group gross profit margin was 53%, and it invested $81.6 million in research and development, a 47% increase year-over-year.

The Precision Medicine segment saw revenue increase by 30% compared to H1 2024, driven by higher Illuccix dose volumes. The segment’s adjusted EBITDA was up by 24% to $104.6 million, with selling and marketing expenses of $40.9 million.

Telix Manufacturing Solutions (TMS) invested in infrastructure to scale operations, with RLS Radiopharmacies (RLS, U.S.) reporting $109.5 million in revenue. The segment’s operating expenses were $30.5 million, including $14.9 million for the RLS business.

Telix Therapeutics reinvested earnings to accelerate its late-stage pipeline, with 54% of total R&D investment going towards therapeutics. Milestones included completing target enrollment for a Phase 3 study in advanced metastatic castration resistant prostate cancer.

Telix confirms revenue guidance of US$770 million to US$800 million for FY 2025, with an expected increase in R&D expenditure of 20% to 25% compared to FY 2024. An investor webcast and conference call will be held on August 21, 2025.

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals. The company is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit www.telixpharma.com for more information.

Read more at GlobeNewswire: Telix 2025 Half-Year Results: Strong commercial performance